News Briefs

Implementation of the most- favored-nation (MFN) model continues to be stalled. Following court rulings in December that temporarily blocked its Jan. 1 enactment (RSP 1/21, p. 8), the U.S. District Court for the District of Maryland issued a joint motion to stay in the case (No. 8:20-cv-03531-GJH) until a final rule that’s based on the MFN interim final rule, which was published in late November, is published in the Federal Register. It requires that the defendants not appeal the preliminary injunction a California court issued and that “the performance period for any final regulation stemming from the MFN Interim Final Rule shall not commence earlier than 60 days” after its publication. View the motion at https://bit.ly/39EfoNw.

A court also has pushed back implementation of the rebate rule until January 2023. The rule would require that drug rebates currently given to plan sponsors would instead be offered to seniors as discounts at the point of sale. It would exclude the rebates given to Part D plans or their PBMs from a safe harbor they now are included in and establish two new safe harbors. However, the Pharmaceutical Care Management Association filed a lawsuit (No. 1:21-cv-00095-JDB) in the U.S. District Court for the District of Columbia against implementation of the rule. On Jan. 30, the court ordered postponement of the provisions set to take effect after Dec. 31, 2021. View the order at https://bit.ly/36zP2uh.

Angela Maas

Angela has an extensive background of editing, reporting and writing for trade and consumer publications. She has written Radar on Specialty Pharmacy (formerly called Specialty Pharmacy News) since she joined AIS Health in 2005 and has broad knowledge of the various issues at play within the space. Before joining AIS Health, she was managing editor at Employee Benefit News and Employee Benefit News Canada and managing editor at HemAware (a hemophilia publication), Lupus Living and Momentum (a multiple sclerosis publication). She has a B.A. in English and an M.A. in British literature from Arizona State University.

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/10/WordPress-Featured-Image-radar-on-specialty-pharmacy-FDA-Extends-Xeljanz-Safety-Warnings-to-Other-JAK-Inhibitors.jpg
October 14

FDA Extends Xeljanz Safety Warnings to Other JAK Inhibitors

READ MORE
https://www.mmitnetwork.com/wp-content/uploads/2021/09/WordPress-Featured_FDA-Requires-Warnings-on-Labels-of-JAK-Inhibitors-for-Inflammatory-Conditions.jpg
October 14

FDA Approves Byooviz, First Ophthalmology Biosimilar in U.S.

READ MORE
https://www.mmitnetwork.com/wp-content/uploads/2021/10/WordPress-Featured-Image-radar-on-specialty-pharmacy-Groups-Warn-Against-Avastin-Biosimilar-Off-Label-Use-in-Eyes.jpg
October 14

Groups Warn Against Avastin Biosimilar Off-Label Use in Eyes

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today